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Introduction: This report summarizes recommendations relating to haemophilia therapy arising from discussions
among experts from 36 European countries during the ‘Kreuth IV’ meeting in May 2016. Aim: The objective of
the meeting was for experts in the field of haemophilia from across Europe to draft resolutions regarding current
issues relating to the treatment of haemophilia. Results: Hospitals providing clinical care for people with
haemophilia and related disorders are strongly recommended to seek formal designation as either European
Haemophilia Treatment Centres (EHTC) or European Haemophilia Comprehensive Care Centres (EHCCC).
There should be agreed national protocols or guidelines on management of the ageing patient with haemophilia.
The minimum consumption of factor VIII and IX concentrate in any country should be 4 IU and 0.5 IU per
capita of general population respectively. Treatment for hepatitis C with direct-acting antiviral agents should be
provided to all people with haemophilia on a priority basis. Genotype analysis should be offered to all patients
with severe haemophilia. Genetic counselling, when given, should encompass the recommendation that genetic
relatives of the affected person be advised to seek genetic counselling. People with inhibitors should have access
to bypassing agents, immune tolerance and elective surgery. National or regional tenders for factor concentrates
are encouraged. Outcome data including health related quality of life should be collected. Treatment with
extended half-life factors should be individualized and protection against bleeding should be improved by
increasing trough levels. Steps should be taken to understand and minimize the risk of inhibitor development.
Conclusion: It is hoped that these recommendations will help to foster equity of haemophilia care throughout
Europe.
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Introduction
This manuscript describes the outcome of delibera-
tions from the latest in a series of meetings devoted to
optimal clinical use of blood components and of
plasma-derived medicinal products with a focus on
the treatment of haemophilia and related disorders in
Europe. These meetings have been convened periodi-
cally under the joint aegis of the Paul Ehrlich Institut
(PEI), the Ludwig-Maximilian-University of Munich
(LMU) and the Council of Europe through its Euro-
pean Department for the Quality of Medicines and
Healthcare (EDQM). It is therefore important to
emphasize that delegates were invited from the 47
member states of the Council of Europe, which covers
a much larger territory than the 28 member states of
the European Union. Previous meetings in this frame-
work were held in Wildbad Kreuth in southern Ger-
many in 1999, 2009 and 2013 [1]. The principal
recommendations which emerged from the last meet-
ing in April 2013 were subsequently endorsed by the
Committee of Ministers of the Council of Europe in
April 2015 (Resolution CM/Res[2015]3). The confer-
ence was an opportunity for nominated delegates from
all Council of Europe member and observer states,
along with colleagues from academia, the European
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Haemophilia Consortium (EHC) and European
Medicines Agency (EMA), to review trends in the use
of coagulation factor concentrates. The three areas
which were set as objectives for discussion in relation
to haemophilia were: critical appraisal of the status
quo and identification of gaps in clinical and outcomes
research in haemophilia; perspectives on innovative
products and identification of best practice; and future
needs in haemophilia care. Participants heard a series
of ‘state of the art’ presentations and then met in
workshops to draw up consensus recommendations
relating to research and regulatory policies concerning
haemophilia therapy in Europe [2]. Data from the lat-
est 2015 survey from the European Haemophilia Con-
sortium (EHC) were presented and discussed [3].
These were very helpful in highlighting both areas
where progress has been made as well as other areas
where further effort is still required to improve the
quality of care. The EHC plans to conduct further sur-
veys on a regular basis in the coming years in order to
monitor adoption of these latest recommendations. It
is also planned to submit these latest recommenda-
tions to the Committee of Ministers of the Council of
Europe as high-level political support will add consid-
erable weight to the recommendations.
Objectives
The aim of the meeting was for experts in the field of
haemophilia from across Europe (including patient
organization representatives, clinicians and regulators)
to draft resolutions regarding current issues relating to
the treatment of haemophilia.
Recommendations of the ‘Kreuth IV’ meeting
Recommendation 1
Hospitals providing clinical care for people with hae-
mophilia and related disorders are strongly recom-
mended to seek formal designation as either European
Haemophilia Treatment Centres (EHTC) or European
Haemophilia Comprehensive Care Centres (EHCCC).
The EUHANET project, funded by the European
Commission, has established criteria for the designa-
tion of two tiers of haemophilia treatment centres,
namely European Haemophilia Treatment Centres
(EHTC) and European Haemophilia Comprehensive
Care Centres (EHCCC) [4]. The ultimate aim of the
project was to standardize the level of care within
Europe and, at the same time, ensure that access to
comprehensive care and replacement therapy is equita-
ble in all parts of individual countries. Key criteria in
the assessment of treatment facilities include the num-
ber of patients treated as well as the range of multidis-
ciplinary support and laboratory test available.
Applications are reviewed by a panel which includes
representatives from both the European Haemophilia
Consortium (EHC) and the European Association for
Haemophilia and Allied Disorders (EAHAD).
Although the system currently relies on self-certifica-
tion, it is hoped to introduce a system of external
audit or accreditation in the future. Participation in
the scheme is not mandatory but over 120 centres
from 30 countries have already applied for certifica-
tion through the scheme.
Recommendation 2
There should be agreed national protocols or guideli-
nes on management of the ageing patient with
haemophilia. Treatment centres are encouraged to
include an appropriate general physician in the com-
prehensive care team.
Improvements in the treatment of haemophilia have
led to a striking increase in longevity of people with
haemophilia in recent years such that life expectancy
now approaches that of the general population. In the
UK, the number of patients with severe haemophilia
aged 60 or more has trebled over the last 40 years [5].
However, the management of elderly people with hae-
mophilia presents new challenges in the form of com-
plex medical problems which many haematologists
will not be accustomed to dealing with, such as car-
diac and respiratory diseases [6]. Paediatricians have
been involved in haemophilia care for decades and a
strong feeling emerged at the conference that the time
has now come to invite physicians experienced in the
care of the elderly to also become part of the multidis-
ciplinary team in haemophilia treatment centres.
Recommendation 3
The minimum consumption of Factor VIII concentrate
in any country should be 4 IU per capita of general
population.
A minimum consumption of 3 IU per capita was
recommended at the Kreuth III meeting in 2013, on
the basis that this was the threshold required to ensure
children could be treated on a prophylactic basis [1].
It is encouraging to see in the most recent EHC survey
from 2015 that Factor VIII consumption has increased
in 22 out of 30 countries since the last survey in
2013. However, national consumption was still below
the threshold of 3 IU per capita in 7 countries [3].
Factor VIII consumption ranged from 0.46 IU per cap-
ita in Albania to 9.4 IU per capita in Hungary. There
has been growing support for prophylactic treatment
of adults in the last few years, based on the results of
the SPINART and other prospective randomized clini-
cal trials [7,8]. Many clinicians now offer secondary
prophylaxis to adults with severe haemophilia, in the
light of results from such studies which have provided
clear evidence of a benefit in terms of both reduction
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in frequency of bleeds as well improvement in quality
of life. In order to encourage and facilitate wider
adoption of prophylaxis in adults, the group recom-
mended a further increase in recommended minimum
Factor VIII consumption in a country to 4 IU per
capita. The group wishes to emphasize that this con-
sumption level is regarded as the minimum acceptable
one and a threshold of 4 IU per capita should not be
viewed by public health authorities as the optimum
level. The group also recommended that data
expressed as units per severe patient should also be
collected in parallel in future. It was also acknowl-
edged that the use of novel coagulation factor concen-
trates with extended half-lives will further complicate
analysis of concentrate use in terms of IU per capita
in the coming years. One solution would be to agree
on a conversion factor for each product based on the
degree of prolongation.
Recommendation 4
The minimum consumption of Factor IX concentrate
in a country should be 0.5 IU per capita of general
population.
Working parties at previous Kreuth meetings have
never before issued a recommendation in relation to
Factor IX consumption. Previous international surveys
have also largely focused on Factor VIII consumption.
After consideration of the data from the 2015 EHC
survey, the group agreed unanimously to recommend
a minimum national Factor IX consumption of 0.5 IU
per capita. This was the median value in the most
recent EHC survey, with a range of from 0.1 IU per
capita in Romania to 2.47 IU per capita in the Repub-
lic of Ireland [3]. The lower consumption level of
Factor IX (compared to factor VIII) reflects the lower
frequency of haemophilia B in the European popula-
tion.
Recommendation 5
Treatment for hepatitis C with direct-acting antiviral
agents should be provided to all people with haemo-
philia on a high priority basis.
Many patients with haemophilia were infected with
hepatitis C (HCV) in the 1970s and 80s, before the
introduction of virucidal techniques such as heat or
solvent/detergent treatment of plasma for fractiona-
tion. HCV infection is typically slow to progress,
often causing few symptoms until cirrhosis or liver
cancer develops after several decades. The EUHASS
survey has shown that hepatocellular carcinoma is
now the leading malignancy diagnosed in people with
haemophilia. Interferon and ribavirin have been used
to treat some patients in the past, but only
approximately half of them achieved sustained viral
eradication with this combination, which was also
associated with significant side-effects. The recent
development of direct-acting antiviral agents such as
sofosbuvir and simeprevir offers a new opportunity to
treat patients with haemophilia although the cost of
treatment is a barrier. The probability of viral eradica-
tion is much higher with these new drugs, which are
also less toxic and administered orally for shorter time
period. The group felt very strongly that people with
haemophilia and related disorders constitute a special
group which merits priority for treatment, given the
iatrogenic source of infection.
Recommendation 6
Genotype analysis should be offered to all patients
with severe haemophilia. Patients shall be free to
decide whether or not to take up this possibility.
Genetic counselling of the affected person, when
given, should encompass the recommendation that
genetic relatives of the affected person be advised to
seek genetic counselling.
A recommendation that genetic counselling should
be available to families affected by haemophilia was
made at the second Kreuth meeting in 2009. No
genetic tests are required, for example, to advise the
daughter of a man with haemophilia that she will be a
carrier of the condition or that the son of an affected
man will be free of the condition. However, the situa-
tion for many women in the wider kindred is not so
clear and can only be established through DNA-based
testing using technology which is now widely avail-
able. This information can then be used to determine
foetal sex early during pregnancy if a women wishes
to undergo antenatal diagnosis with a view to termi-
nation of an affected pregnancy (in countries where
this is permitted by law). Knowledge of the particular
genotype responsible for haemophilia in a patient can
also be used to give an indication of the risk of inhibi-
tor development. Although patients with a severe phe-
notype should be prioritized for genetic studies,
genotyping is also desirable in cases of mild and mod-
erate haemophilia and for patients with other congeni-
tal bleeding disorders.
Recommendation 7
People with inhibitors should have access to immune
tolerance.
A prospective international trial of immune toler-
ance induction has provided clear evidence that the
majority of patients with haemophilia A and inhibi-
tors achieve tolerance: 70% of patients achieved com-
plete tolerance and a further 5% achieved a partial
response [9]. Although the infusion of high doses of
Factor VIII for prolonged periods requires a high
financial outlay, this is cost effective in the longer
term through the avoidance of repeated treatment of
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bleeding episodes with much more expensive bypass-
ing agents. A recommendation that all patients with
inhibitors should be offered immune tolerance was
made at the very first Kreuth meeting in 1999. How-
ever, the most recent EHC survey also provides evi-
dence that immune tolerance induction therapy is still
not readily available in several European countries
and so the group felt it important to promulgate this
recommendation again.
Recommendation 8
People with inhibitors should have access to elective
surgery at a specialist centre with relevant experience.
It is now accepted that surgery in patients with
haemophilia and inhibitors can now be performed
safely using bypassing agents [10,11]. Despite the
considerable experience and number of publications
in this field, it is still that case that patients with
inhibitors are denied elective surgery such as arthro-
plasty which could improve their quality of life [12].
In part, this is because some treatment centres still
harbour reservations about the potential for bleeding
but it is also recognized that the initial high cost may
be a considerable barrier. However, a number of eco-
nomic evaluations indicate that surgery may prove
cost effective in the longer term [13,14]. The firm
opinion of the group was that surgery in patients
with inhibitors should only be carried out in centres
with previous experience. Where this is not feasible
locally, patients should be referred to another centre
with the requisite experience (across national borders
if necessary).
Recommendation 9
National or regional tenders for factor concentrates
are encouraged and should always include both hae-
mophilia clinicians and national haemophilia patient
representatives.
The cost of coagulation factor concentrates accounts
for around 80% of the overall budget for haemophilia
care [15,16]. If a budget is limited, then the ability to
purchase product at a low price is vital in order to
maximize the volume purchased. A recent interna-
tional survey has demonstrated that tenders are a very
effective way to reduce prices through open competi-
tion between manufacturers [17]. This study empha-
sized that the best outcome in terms of price was
obtained when both haemophilia physicians as well as
patient representatives were engaged in the process. In
the UK, the price of recombinant Factor VIII was
almost halved after a series of competitive tenders
[18]. The process was fully supported by patients in
the UK and no increased risk of inhibitor development
was observed after product switching [19]. Of course,
as already pointed out through the Kreuth III
recommendations, cost should not be the sole consid-
eration in product tenders: product safety should
always be the primary selection criterion.
Recommendation 10
Outcome data including health related quality of life
should be collected with appropriate study design, e.g.
annualized bleed rates (ABR), mortality, joint score
and time off from education or employment.
The group recognized that both clinicians and
health agencies which purchase products for the treat-
ment of haemophilia face an increasingly difficult task
in choosing the most appropriate products at a time
when so many novel products become available. For-
mal health technology assessments play an ever
increasing role in product selection. Data on novel
products must be collected during routine reviews and
be used by clinicians to persuade payers to adopt
novel products. Ideally, such data from individual
treatment centres should also be collated at national
level through a database. Formal clinical trials also
have an increasingly important role in providing
objective data. The appropriate study design depends
on the study question and, for this, the correct termi-
nology needs to be used:
Case series: group of patients on whom cross-sec-
tional data are collected
Register: database that contains information on all
inhabitants of a country, or a complete subset of
those, i.e. all patients with a certain disorder
Cohort: a group that is followed over time
Randomised trial: a cohort with two arms defined
by an intervention, which has been allocated by a
random process.
Recommendation 11
Treatment with extended half-life factors should be
individualized and protection against bleeding should
be improved by increasing trough levels.
A number of novel coagulation factor concentrates
with extended half-lives have been developed, some of
which are already licensed in some countries. Per-
ceived advantages of these products include a reduc-
tion in the frequency of venepuncture and the
attainment of higher trough levels than the current
conventional target of 1% (0.01 IU ml1). The bene-
fits are particularly evident for longer-acting novel
Factor IX products, as these have a 5-fold increase in
half-life as compared to a much more modest 1.5-fold
increase for novel factor VIII products. Many advo-
cate the adoption of higher trough levels of up to
15% as this would minimize the risk of bleeding and
allow patients to lead more active lives [20]. However,
the group could not reach consensus on what the
desirable minimum trough levels should be with such
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new agents and further research is required in this
area. It was recognised that treatment regimens should
be individualized, according to the lifestyle and indi-
vidual pharmacokinetics in each patient. However,
treatment regimens should not be dictated by trough
and peak levels alone. The primary parameter to guide
treatment should be the frequency of bleeds: as recent
UK guidelines on the clinical utilization of these novel
products emphasize, the goal in children should be an
annualized bleeding rate of 0 [21].
Recommendation 12
There is increasing evidence that the incidence of inhi-
bitors amongst previously untreated patients (PUPs)
varies between products. Steps should be taken to
understand and minimize this risk.
Now that the reduction of the risk of transmission
of pathogens like HIV and hepatitis through plasma-
derived medicinal products has effectively been maxi-
mized, the development of inhibitors has become the
principal complication of haemophilia therapy. The
SIPPET study reported a significantly increased risk of
inhibitor developments amongst previously untreated
patients (PUP) who received recombinant Factor VIII
products, when compared to subjects who received
plasma-derived products [22]. Other factors which
have been implicated in the appearance of inhibitors
in PUPs include ethnicity, intensity of early treatment
and early prophylaxis [23]. Patients, or parents in the
case of young children, should be involved in discus-
sions related to product choice and usage during the
early period of treatment. It is now also recognized
that a significant proportion of patients with
non-severe haemophilia can develop inhibitors after
treatment with coagulation factor concentrates. Adults
with mild haemophilia who, for example, undergo
minor invasive procedures such as dental extractions
should be checked for treatment status in relation to
coagulation factors. In cases where they are still effec-
tively PUPs and in the vulnerable period of <50 expo-
sure days, the use of desmopressin (DDAVP) instead
of coagulation factor concentrates will reduce the risk
of inhibitor development.
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